☆ 4.4 Review

Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence

INTERNAL AND EMERGENCY MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Letter Immunology

The Right Time for Steroids in COVID-19

Ana Fernandez-Cruz et al.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial

Christiane Maria Prado Jeronimo et al.

Summary: This study evaluated the efficacy of methylprednisolone (MP) among hospitalized patients with suspected COVID-19 and found that a short course of MP did not reduce mortality in the overall population. However, patients over 60 years old in the MP group had a lower mortality rate, suggesting potential benefits for this age group.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Virology

Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19

Stephen M. Smith et al.

Summary: The study analyzed clinical characteristics associated with severe COVID-19 in 184 hospitalized patients in Livingston, New Jersey, and found that diabetes was common among COVID-19 patients and severe disease was often accompanied by impaired glucose metabolism.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Letter Immunology

Corticosteroid-related In-Hospital Hyperglycemia: Does It Negate Mortality Benefits in Coronavirus Disease 2019?

Chia Siang Kow et al.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study

Michele Bartoletti et al.

Summary: The study aimed to evaluate the efficacy of corticosteroids in treating COVID-19 patients. Results showed that corticosteroid treatment did not significantly reduce 30-day mortality overall, but in patients with PO2/FiO2 < 200 mm Hg at admission, corticosteroid treatment was associated with a lower risk of 30-day mortality.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Computational pathology reveals unique spatial patterns of immune response in H&E images from COVID-19 autopsies: preliminary findings

German Corredor et al.

Summary: The study used computerized image analysis and machine learning approaches to characterize immune response features in the lung tissue of COVID-19 patients. The results showed smaller lymphocyte clusters in COVID-19 and larger lymphocyte clusters in H1N1, reflecting potential differences in immune response patterns between the two diseases.

JOURNAL OF MEDICAL IMAGING (2021)

Add to Collection

Article Medicine, General & Internal

Avascular necrosis as a part of 'long COVID-19'

Sanjay R. Agarwala et al.

Summary: 'Long COVID-19' can lead to AVN, which has not been documented yet, but the increased use of corticosteroids for treating COVID-19 may result in more cases of AVN.

BMJ CASE REPORTS (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine et al.

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial

Carlo Salvarani et al.

Summary: This study evaluated the use of tocilizumab in hospitalized COVID-19 pneumonia patients and found no significant benefit compared to standard care. Further randomized clinical trials with blinded, placebo-controlled methods are needed to confirm these results and explore potential applications of tocilizumab in different stages of the disease.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

WHO recommends corticosteroids for patients with severe or critical COVID-19

Holly Keyt

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

Add to Collection

Review Medicine, General & Internal

COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs

Alessandra Bartoli et al.

Summary: There is currently no specific therapy for COVID-19 disease, and clinical studies have methodological limitations. Different categories of drugs have varying efficacy at different stages of the disease, emphasizing the need for further well-designed clinical trials to establish a standard of care for COVID-19.

INTERNAL AND EMERGENCY MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Respiratory System

Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial

Xiao Tang et al.

Summary: The study did not find a benefit of short-term early use of corticosteroids in treating patients with COVID-19 pneumonia in terms of clinical deterioration, but it may prolong the shedding of the virus. The number of immune cells was significantly reduced in the treatment group.

RESPIRATION (2021)

Add to Collection

Article Medicine, General & Internal

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Viviane C. Veiga et al.

Summary: The study found that in patients with severe or critical COVID-19, tocilizumab in combination with standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Letter Critical Care Medicine

Corticosteroids for COVID-19: the search for an optimum duration of therapy

Gyanshankar P. Mishra et al.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Immunology

Dysregulated Host Response in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Critical Illness

Shilpa Tiwari-Heckler et al.

Summary: The study found that critically ill patients with COVID-19 exhibited low levels of CD8 T cells and myeloid dendritic cells, along with a TH17-mediated response and dysfunctional IFN-associated response. Immunophenotyping also revealed some characteristics of the immune response.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Article Critical Care Medicine

Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes Systematic Review and Meta-analysis

Edison J. Cano et al.

Summary: A systematic review of literature on corticosteroids and COVID-19 found evidence of mortality benefit in severely ill COVID-19 patients treated with corticosteroids. However, there were no significant differences in outcomes between high-dose and low-dose corticosteroid regimens. Low-dose corticosteroids do not appear to significantly impact the duration of SARS-CoV-2 viral shedding based on emerging evidence. Further high-quality clinical trials are needed to determine the most beneficial timing and dosing for corticosteroids in the rapidly evolving global pandemic.

CHEST (2021)

Add to Collection

Article Pharmacology & Pharmacy

Glucocorticoids impair type I IFN signalling and enhance rhinovirus replication

Andrea Marcellini et al.

Summary: The study found that inhaled corticosteroids may inhibit the innate antiviral immune response, leading to an increase in viral replication. This could have significant clinical implications.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients

Amit Bahl et al.

Summary: The study analyzed 1461 hospitalized COVID-19 patients and found that those receiving corticosteroid therapy had a lower risk of death. Patients who received their first dose of corticosteroids after 72 hours and those who started corticosteroids more than 7 days after symptom onset had a lower risk of death.

INTERNAL AND EMERGENCY MEDICINE (2021)

Add to Collection

Review Dermatology

The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis

Kazem Ahmadikia et al.

Summary: Acute respiratory distress syndrome is a common complication of severe viral pneumonia, requiring critical care with corticosteroids, but steroid therapy can lead to secondary fungal infections, with diabetes being a risk factor for mucormycosis.

MYCOSES (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Factors associated with delayed viral shedding in COVID-19 infected patients: A retrospective small-scale study

Hui-ru Cao et al.

Summary: This retrospective study on 87 hospitalized patients in Suzhou identified excessive cumulative corticosteroid use, hospitalization within 5 days from illness onset, and arbidol-included therapy as independent risk factors for delayed COVID-19 RNA shedding. These findings could help clinicians tailor treatment strategies for patients with delayed viral shedding.

RESPIRATORY MEDICINE (2021)

Add to Collection

Review Chemistry, Medicinal

Beware of Steroid-Induced Avascular Necrosis of the Femoral Head in the Treatment of COVID-19-Experience and Lessons from the SARS Epidemic

Shenqi Zhang et al.

Summary: The recent global outbreak of COVID-19 has raised important questions regarding the use of corticosteroid therapy, dosage, and duration, as well as prevention, early detection, and timely intervention of SANFH. Due to possible biases in the data selection and lack of large-scale research data support, more studies are needed to establish the gold standard for these issues.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

Add to Collection

Review Respiratory System

Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?

Ignacio Martin-Loeches et al.

Summary: Corticosteroids have been widely used in medicine, especially in the treatment of infectious diseases. Recent studies have focused on their role in conditions like community-acquired pneumonia and COVID-19, showing that in some cases, their use can lead to improved survival rates.

EUROPEAN RESPIRATORY REVIEW (2021)

Add to Collection

Article Virology

Risk factors for bacterial infections in patients with moderate to severe COVID-19: A case-control study

Nosheen Nasir et al.

Summary: This study found that adverse outcomes in COVID-19 patients are often due to bacterial coinfection, with risk factors including critical illness at presentation and use of steroids. There is also a widespread use of empiric antibiotics in patients without bacterial infection.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Nicholas G. Davies et al.

Summary: Studies have shown that the SARS-CoV-2 B.1.1.7 lineage is more transmissible and may cause more severe illness compared to pre-existing variants.

NATURE (2021)

Add to Collection

Article Cell Biology

High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages

Willianne Hoepel et al.

Summary: Patients diagnosed with COVID-19 tend to become critically ill around the activation of the adaptive immune response. Evidence shows that antibodies in serum may worsen the disease during seroconversion. High anti-spike IgG levels in critically ill patients with severe COVID-19 induce excessive inflammatory responses and may lead to pulmonary complications such as microvascular thrombosis.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Prasanna Jagannathan et al.

Summary: A randomized, single-blind, placebo-controlled trial on 120 outpatients with mild to moderate COVID-19 showed that a single subcutaneous dose of Peginterferon Lambda-1a (Lambda) did not shorten the duration of SARS-CoV-2 viral shedding or improve symptoms. The treatment was well tolerated but did not have a significant impact on the outcomes of the patients.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival

Stefania Dispinseri et al.

Summary: The study reveals that antibody responses to SARS-CoV-2 spike protein play a significant role in neutralization and protection against severe COVID-19, unaffected by heterologous boosting or common cold immunity, and can last for up to 8 months.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Medicine, General & Internal

Avascular Necrosis in Patients Recovering from COVID-19

Parva Namiranian et al.

AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Chang Liu et al.

Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.

CELL (2021)

Add to Collection

Article Medicine, General & Internal

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis

Manu Shankar-Hari et al.

Summary: This study identified 27 clinical trials and found that the use of IL-6 antagonists was associated with lower 28-day all-cause mortality in patients hospitalized for COVID-19 compared to usual care or placebo. Different risk effects were observed between tocilizumab and sarilumab, increasing understanding of the treatment with these drugs.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Editorial Material Medicine, General & Internal

IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19 Who, When, and How?

Michael A. Matthay et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Patricia O. Guimaraes et al.

Summary: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. The mortality rate was lower in the tofacitinib group within 28 days. However, the rate of serious adverse events was similar in both groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

JAK Inhibitors - More Than Just Glucocorticoids

Justin Stebbing et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Bacterial superinfection in adults with COVID-19 hospitalized in two clinics in Medellin-Colombia, 2020

Juan Carlos Catano-Correa et al.

Summary: The prevalence of bacterial superinfections in adult COVID-19 patients hospitalized in two clinics in Medellin-Colombia during 2020 was found to be 49.6%, with Klebsiella and Staphylococcus aureus being the most frequent pathogens. Factors strongly associated with bacterial superinfection included lung disease, encephalopathy, mechanical ventilation, hospital stay, and steroid treatment.

PLOS ONE (2021)

Add to Collection

Article Critical Care Medicine

The Impact of Corticosteroids on Secondary Infection and Mortality in Critically Ill COVID-19 Patients

Lindsay A. Ritter et al.

Summary: This study included 135 critically ill patients with COVID-19, finding a 63% rate of secondary infection. The research results indicate that the use of corticosteroids does not increase the risk of secondary infection, but can significantly reduce mortality, especially within 28 days.

JOURNAL OF INTENSIVE CARE MEDICINE (2021)

Add to Collection

Review Respiratory System

The role of co-infections and secondary infections in patients with COVID-19

Charles Feldman et al.

Summary: The current review provides an extensive look at the prevalence of co-infections and superinfections in patients with COVID-19, highlighting their potential impact on the severity and outcome of the disease. However, a clear distinction between the two types of infections is often lacking in the literature.

PNEUMONIA (2021)

Add to Collection

Article Respiratory System

Impact of corticosteroids in hospitalised COVID-19 patients

Kam Sing Ho et al.

Summary: This study found that the use of corticosteroids within the first 7 days of hospital admission for COVID-19 patients can reduce mortality and ICU admissions, particularly in younger age groups, females, and patients with elevated inflammatory markers.

BMJ OPEN RESPIRATORY RESEARCH (2021)

Add to Collection

Letter Biochemistry & Molecular Biology

Prognostic value of lymphocyte count in severe COVID-19 patients with corticosteroid treatment

Chenyang Lu et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials

Shaolei Ma et al.

Summary: Current clinical trials suggest that corticosteroid use may reduce overall mortality in severe COVID-19 patients, decrease disease progression, and not increase the incidence of serious adverse events. However, more trials are needed to confirm these results.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Article Medicine, General & Internal

Steroid harms if given early in COVID-19 viraemia

Kanupriya Arora et al.

Summary: COVID-19 is a biphasic illness, with immune regulation being key to treatment, and early preventive medication may worsen the condition.

BMJ CASE REPORTS (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Clark D. Russell et al.

LANCET (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

Add to Collection

Article Endocrinology & Metabolism

The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan

Yang Zhang et al.

DIABETES OBESITY & METABOLISM (2020)

Add to Collection

Review Immunology

Immunology of COVID-19: Current State of the Science

Nicolas Vabret et al.

IMMUNITY (2020)

Add to Collection

Letter Medicine, General & Internal

Antagonizing the renin-angiotensin-aldosterone system in the era of COVID-19

Riccardo Sarzani et al.

INTERNAL AND EMERGENCY MEDICINE (2020)

Add to Collection

Review Infectious Diseases

The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis

Zhenwei Yang et al.

JOURNAL OF INFECTION (2020)

Add to Collection

Review Oncology

Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis

Huan Li et al.

LEUKEMIA (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody responses to SARS-CoV-2 in patients with COVID-19

Quan-Xin Long et al.

NATURE MEDICINE (2020)

Add to Collection

Article Microbiology

A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality

Ana Fernandez-Cruz et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Endocrinology & Metabolism

Managing Hyperglycemia in the COVID-19 Inflammatory Storm

Roma Gianchandani et al.

DIABETES (2020)

Add to Collection

Article Medicine, General & Internal

Bloodstream infections in critically ill patients with COVID-19

Daniele Roberto Giacobbe et al.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Review Immunology

Immune Response, Inflammation, and the Clinical Spectrum of COVID-19

Luis F. Garcia

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Presence of Genetic Variants Among Young Men With Severe COVID-19

Caspar I. van der Made et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Letter Endocrinology & Metabolism

Corticosteroid-Induced Osteonecrosis in COVID-19: A Call For Caution

Bin Zhang et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19

Marla J. Keller et al.

JOURNAL OF HOSPITAL MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Takuya Sekine et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Carolyn Rydyznski Moderbacher et al.

CELL (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Chee Wah Tan et al.

NATURE BIOTECHNOLOGY (2020)

Add to Collection

Article Endocrinology & Metabolism

Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration

Gian Paolo Fadini et al.

DIABETES RESEARCH AND CLINICAL PRACTICE (2020)

Add to Collection

Article Multidisciplinary Sciences

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Jerome Hadjadj et al.

SCIENCE (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial

Pierre-Francois Dequin et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial

Bruno M. Tomazini et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Immunology

Broad and strong memory CD4+and CD8+T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Yanchun Peng et al.

NATURE IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

John H. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Multidisciplinary Sciences

Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Jude Moutchia et al.

PLOS ONE (2020)

Add to Collection

Article Multidisciplinary Sciences

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Qian Zhang et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Paul Bastard et al.

SCIENCE (2020)

Add to Collection

Article Microbiology

Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2

Idoia Busnadiego et al.

MBIO (2020)

Add to Collection

Review Medicine, General & Internal

Cytokine Storm

David C. Fajgenbaum et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Immunology

Control of immunity by glucocorticoids in health and disease

Akihiro Shimba et al.

SEMINARS IN IMMUNOPATHOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19

V Spagnuolo et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Medicine, Research & Experimental

Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome

Jiao Liu et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Article Critical Care Medicine

Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study

Yiming Li et al.

CRITICAL CARE (2020)

Add to Collection

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

Add to Collection

Article Critical Care Medicine

Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis

Chaomin Wu et al.

CRITICAL CARE (2020)

Add to Collection

Review Endocrinology & Metabolism

Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2

Morag J. Young et al.

JOURNAL OF ENDOCRINOLOGY (2020)

Add to Collection

Letter Critical Care Medicine

Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series

Jie Wang et al.

CRITICAL CARE (2020)

Add to Collection

Article Immunology

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Miriam Merad et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Article Critical Care Medicine

Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China

Dawei Wang et al.

CRITICAL CARE (2020)

Add to Collection

Review Immunology

The trinity of COVID-19: immunity, inflammation and intervention

Matthew Zirui Tay et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza

Timothy M. Uyeki et al.

CLINICAL INFECTIOUS DISEASES (2019)

Add to Collection

Review Critical Care Medicine

The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis

Yue-Nan Ni et al.

CRITICAL CARE (2019)

Add to Collection

Review Medicine, General & Internal

Corticosteroids as adjunctive therapy in the treatment of influenza

Louise Lansbury et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)

Add to Collection

Article Critical Care Medicine

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

Yaseen M. Arabi et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)

Add to Collection

Editorial Material Critical Care Medicine

Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus Infection

David S. Hui

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)

Add to Collection

Article Endocrinology & Metabolism

Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis

R. Zhao et al.

OSTEOPOROSIS INTERNATIONAL (2017)

Add to Collection

Article Infectious Diseases

Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis

J-W. Yang et al.

CLINICAL MICROBIOLOGY AND INFECTION (2015)

Add to Collection

Article Orthopedics

High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review

Michael A. Mont et al.

JOURNAL OF ARTHROPLASTY (2015)

Add to Collection

Article Multidisciplinary Sciences

Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon

Belinda J. Thomas et al.

SCIENTIFIC REPORTS (2014)

Add to Collection

Article Critical Care Medicine

The Effect of Steroid Use in Hospitalized Adults With Respiratory Syncytial Virus-Related Illness

F. Eun-Hyung Lee et al.

CHEST (2011)

Add to Collection

Article Biochemistry & Molecular Biology

The Type I Interferon Signaling Pathway Is a Target for Glucocorticoid Inhibition

Jamie R. Flammer et al.

MOLECULAR AND CELLULAR BIOLOGY (2010)

Add to Collection

Review Medicine, General & Internal

Use of corticosteroids in treating infectious diseases

Steven McGee et al.

ARCHIVES OF INTERNAL MEDICINE (2008)

Add to Collection

Article Medicine, General & Internal

A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis

Howard M. Corneli et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Add to Collection

Article Virology

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

N Lee et al.

JOURNAL OF CLINICAL VIROLOGY (2004)

Add to Collection

Article Respiratory System

Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak

JJY Sung et al.

THORAX (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.